Could 2023 be a boom year for orthopedic devices?

2023-02-09
并购
GlobalData predicts the orthopedic surgical robotics space will be even hotter this year, growing 25.6% year-over-year to $984 million. “Boosted by artificial intelligence (AI) and machine learning, new generations of orthopedic robots are expected to further improve clinical outcomes. Unlike the general surgery robotics market — which is dominated by only one company, Intuitive Surgical — all major orthopedic manufacturers are competing in the orthopedic robotics market,” Tina Deng, principal medical devices analyst at GlobalData, said in a news release posted Feb. 1. In addition, Global Data noted that the pandemic has accelerated the shift of procedures to outpatient or ambulatory surgical centers. Recent orthopedic device industry news on MassDevice appears to back up the GlobalData report. For example, orthopedic device giant Stryker is starting the year with good momentum. Plus, it plans new application launches in 2024 for its popular Mako robotic surgery system. “The fourth quarter was almost back to normal,” CEO Kevin Lobo told Fox Business in a recent interview. He predicted a tailwind for the next couple of years. Lobo acknowledged that high electronics costs had affected its capital equipment business. But he told Fox Business that Stryker has started a years-long process of raising prices and cutting costs to restore margins to 2019 levels. In 2021, Stryker acquired Gauss Surgical and its Triton artificial intelligence-enabled platform for the real-time monitoring of blood loss during surgery. Gauss Surgical founder Siddarth Satish is now leading a Stryker AI initiative inside the company’s Digital, Robotics, and Enabling Technologies business, Lobo said. In other orthopedic device company news, Zimmer Biomet is looking to achieve attractive growth after a Street-beating fourth quarter. Meanwhile, smaller companies are combining. Orthofix and SeaSpine completed a merger last month, and Globus Medical and NuVasive announced plans for a combination today.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。